Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LPTX NASDAQ:NERV NASDAQ:PRPH NASDAQ:RWOD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLPTXLeap Therapeutics$0.31-1.3%$0.35$0.22▼$4.79$12.85M-0.27331,448 shs213,029 shsNERVMinerva Neurosciences$1.93+2.9%$1.80$1.15▼$3.00$13.37M-0.3220,799 shs2,623 shsPRPHProPhase Labs$0.33-9.3%$0.38$0.22▼$3.08$14.94M-0.41986,704 shs785,137 shsRWODRedwoods Acquisition$0.73$0.93$2.22▼$13.10$3.75MN/A108,185 shs22,784 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLPTXLeap Therapeutics-1.29%-14.93%+6.25%-27.19%-85.70%NERVMinerva Neurosciences+0.79%-9.62%+12.90%+13.24%-35.19%PRPHProPhase Labs-9.34%-30.04%-19.22%-1.39%-89.34%RWODRedwoods Acquisition0.00%0.00%0.00%0.00%-46.62%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLPTXLeap Therapeutics1.8947 of 5 stars3.04.00.00.00.60.01.3NERVMinerva Neurosciences2.7486 of 5 stars3.03.00.04.60.00.01.3PRPHProPhase Labs0.6311 of 5 stars0.05.00.00.00.60.00.6RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLPTXLeap Therapeutics 2.00Hold$3.381,002.94% UpsideNERVMinerva Neurosciences 2.00Hold$5.00159.74% UpsidePRPHProPhase Labs 0.00N/AN/AN/ARWODRedwoods Acquisition 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLPTXLeap TherapeuticsN/AN/AN/AN/A$0.91 per shareN/ANERVMinerva NeurosciencesN/AN/A$0.22 per share8.95($3.67) per shareN/APRPHProPhase Labs$5.85M2.32N/AN/A$0.25 per share1.30RWODRedwoods AcquisitionN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLPTXLeap Therapeutics-$67.56M-$1.70N/AN/AN/AN/A-162.15%-120.05%8/11/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.35N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)PRPHProPhase Labs-$53.36M-$1.26N/AN/AN/AN/A-184.38%-64.59%8/13/2025 (Estimated)RWODRedwoods AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/ALatest RWOD, NERV, PRPH, and LPTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025PRPHProPhase Labs-$0.15N/AN/AN/A$3.55 millionN/A8/11/2025Q2 2025LPTXLeap Therapeutics-$0.29N/AN/AN/AN/AN/A8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/20/2025Q1 2025PRPHProPhase Labs-$0.18-$0.12+$0.06$0.12$2.45 million$1.43 million5/13/2025Q1 2025LPTXLeap Therapeutics-$0.38-$0.37+$0.01-$0.37N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLPTXLeap TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ARWODRedwoods AcquisitionN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLPTXLeap TherapeuticsN/A2.412.41NERVMinerva NeurosciencesN/A9.219.21PRPHProPhase Labs0.301.030.98RWODRedwoods AcquisitionN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLPTXLeap Therapeutics30.46%NERVMinerva Neurosciences34.56%PRPHProPhase Labs9.45%RWODRedwoods Acquisition20.07%Insider OwnershipCompanyInsider OwnershipLPTXLeap Therapeutics7.50%NERVMinerva Neurosciences8.60%PRPHProPhase Labs9.60%RWODRedwoods Acquisition2.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLPTXLeap Therapeutics4041.44 million38.33 millionOptionableNERVMinerva Neurosciences96.99 millionN/ANot OptionablePRPHProPhase Labs13041.54 million37.55 millionOptionableRWODRedwoods AcquisitionN/A5.17 million5.06 millionNot OptionableRWOD, NERV, PRPH, and LPTX HeadlinesRecent News About These CompaniesGM teams up with Redwood Materials to power data centers with EV batteriesJuly 16, 2025 | msn.comCal Redwood Acquisition Corp. Announces Pricing of $200 Million Initial Public OfferingMay 23, 2025 | bakersfield.comBRedwood Holdings Limited vow to return Reading ‘to its rightful place in English football’ after completing takeoverMay 15, 2025 | nytimes.comRedwood Services Makes 19th AcquisitionMay 15, 2025 | achrnews.comARedwood Announces Investment by Atlas PartnersMay 9, 2025 | achrnews.comARedwood Materials preps for expansion spree with new R&D center in San FranciscoApril 2, 2025 | msn.comBlank-Check Company Cal Redwood Files for IPOMarch 4, 2025 | marketwatch.comEnvironmental Groups Praise Plan to Conserve Coastal Redwoods, Expand Protected LandFebruary 20, 2025 | sanjoseinside.comS$24 million land deal creates 7-mile-long Bay Area corridor of protected redwood forests to the oceanFebruary 12, 2025 | msn.comSave the Redwoods League signs $24 million deal to purchase Monte Rio redwood forest and expand county parkFebruary 12, 2025 | pressdemocrat.comP$24 million land deal creates 7-mile long corridor of protected redwood forests to the oceanFebruary 11, 2025 | eastbaytimes.comERedwood Gospel Mission finalizes purchase of former SAY Dream Center in Santa RosaJanuary 5, 2025 | pressdemocrat.comPRedwood Empire Whiskey Acquires Luxury Northern California DistilleryDecember 21, 2024 | markets.businessinsider.comAcacia Capital buys Redwood City apartments for $184MNovember 13, 2024 | therealdeal.comTRedwood Realty Negotiates $6.6M Sale of Jersey City Apartment BuildingOctober 24, 2024 | rebusinessonline.comRSave the Redwoods League acquires 750 acres of Redwood Forest in Sonoma and Mendocino Counties for future parks expansionsOctober 13, 2024 | ukiahdailyjournal.comUOne of California's most popular old-growth redwood parks is about to get biggerOctober 11, 2024 | msn.comSave the Redwood League acquires 750 acres of land to expand Montgomery Woods, Armstrong WoodsOctober 11, 2024 | mendovoice.comMRedwood Gospel Mission in line to buy former SAY Dream Center campus in Santa RosaOctober 6, 2024 | pressdemocrat.comPBMW of North America partners with Redwood MaterialsSeptember 27, 2024 | recyclingtoday.comRNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military Spend3 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 2025View 3 Short Squeeze Candidates With Big Catalysts on the HorizonHow a Government Loan Changes the Game for Plug PowerBy Jeffrey Neal Johnson | July 4, 2025View How a Government Loan Changes the Game for Plug PowerAmerica Wants Drone Dominance: Are These Stocks Ready to Soar?By Chris Markoch | July 20, 2025View America Wants Drone Dominance: Are These Stocks Ready to Soar?Will Hims & Hers Fall Along With Novo Nordisk?By Gabriel Osorio-Mazilli | August 1, 2025View Will Hims & Hers Fall Along With Novo Nordisk?RWOD, NERV, PRPH, and LPTX Company DescriptionsLeap Therapeutics NASDAQ:LPTX$0.31 0.00 (-1.29%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.31 0.00 (0.00%) As of 08/1/2025 06:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.Minerva Neurosciences NASDAQ:NERV$1.92 +0.06 (+2.94%) Closing price 08/1/2025 03:45 PM EasternExtended Trading$1.92 0.00 (0.00%) As of 08/1/2025 04:13 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.ProPhase Labs NASDAQ:PRPH$0.33 -0.03 (-9.34%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$0.32 0.00 (-0.95%) As of 08/1/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York.Redwoods Acquisition NASDAQ:RWODRedwoods Acquisition Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, stock purchase, recapitalization, reorganization, or other similar business combination with one or more businesses or entities. In intends to focus on businesses in the carbon neutral and energy storage industries. The company was incorporated in 2021 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
